Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Gilead Sciences Inc GILD

Healthcare Biotechnology
Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, COVID-19, cancer and inflammation. It is focused on discovering, developing and delivering medicines to address unmet medical needs in virology, oncology and other therapeutic areas. Its... see more

Recent & Breaking News (NDAQ:GILD)

European Commission Grants Marketing Authorization for Gilead's Harvoni®? (Ledipasvir/Sofosbuvir), the First Single Tablet Regimen to Treat the Majority of Chronic Hepatitis C Patients With Genotype 1 and 4

Business Wire November 18, 2014

Gilead Prices $4 Billion of Senior Unsecured Notes

Business Wire November 12, 2014

Gilead Announces Phase 2 Data for Investigational All-Oral Regimen of Sofosbuvir Plus GS-5816 for the Treatment of Chronic Hepatitis C

Business Wire November 11, 2014

Gilead Announces Harvoni Study Results in Chronic Hepatitis C Patients with Advanced Liver Disease and Those Who Failed Prior Treatment

Business Wire November 11, 2014

Gilead Submits New Drug Application to U.S. Food and Drug Administration for Tenofovir Alafenamide (TAF)-Based Single Tablet Regimen for HIV

Business Wire November 6, 2014

BTV Episode #300 Featuring Gilead, Cynapsus and biOasis

Marketwired November 6, 2014

Gilead Sciences Announces Third Quarter 2014 Financial Results

Business Wire October 28, 2014

Gilead Sciences to Release Third Quarter 2014 Financial Results on Tuesday, October 28, 2014

Business Wire October 21, 2014

Health Canada issues notice of compliance for Gilead's Harvoni(TM) (ledipasvir/sofosbuvir), the first once-daily single tablet regimen for the treatment of genotype 1 chronic hepatitis C

Canada NewsWire October 16, 2014

U.S. Food and Drug Administration Approves Gilead's Harvoni® (Ledipasvir/Sofosbuvir), the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C

Business Wire October 10, 2014

European CHMP Adopts Positive Opinion for Gilead's Harvoni® (Ledipasvir/Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection in Adults

Business Wire September 26, 2014

Gilead's Investigational Tenofovir Alafenamide (TAF)-Based Single Tablet HIV Regimen Meets 48-Week Primary Objective in Two Phase 3 Studies

Business Wire September 24, 2014

Gilead Submits New Drug Application to Japan's Pharmaceutical and Medical Devices Agency for Fixed-Dose Combination of Ledipasvir/Sofosbuvir for Chronic Hepatitis C Genotype 1 Infection

Business Wire September 24, 2014

European Commission Grants Marketing Authorization for Gilead's Zydelig® (Idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma

Business Wire September 19, 2014

Gilead Announces Data From Phase 2 Study of Simtuzumab for Previously Untreated Pancreatic Cancer

Business Wire September 17, 2014

Gilead Announces Generic Licensing Agreements to Increase Access to Hepatitis C Treatments in Developing Countries

Business Wire September 15, 2014

First-Line Combination of Ambrisentan and Tadalafil Reduces Risk of Clinical Failure Compared to Monotherapy in Pulmonary Arterial Hypertension Outcomes Study

Business Wire September 8, 2014

Gilead Sciences to Present at Two Upcoming Investor Conferences in September

Business Wire September 3, 2014

European CHMP Adopts Positive Opinion for Gilead's Zydelig® (idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma

Business Wire July 25, 2014

Galectin, Intercept, Others Vying for Lead Drugs in NASH Epidemic

ACCESS Newswire July 24, 2014